Target Name: ZNF286A
NCBI ID: G57335
Review Report on ZNF286A Target / Biomarker Content of Review Report on ZNF286A Target / Biomarker
ZNF286A
Other Name(s): Z286A_HUMAN | Zinc finger protein 286A (isoform 2) | ZNF286 | KIAA1874 | MGC149627 | zinc finger protein ZNF286 | zinc finger protein 286A | ZNF286A variant 2 | Zinc finger protein 286A | Zinc finger protein ZNF286 | Zinc finger protein 286 | MGC156181 | Zinc finger protein 286A, transcript variant 2

ZNF286A: A Potential Drug Target and Biomarker for Human Diseases

Introduction

ZNF286A, also known as Z286A_HUMAN, is a gene that encodes for a protein known as ZNF286A. ZNF286A is a non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues, including the brain. It is a key regulator of various cellular processes that are essential for human health and development. ZNF286A has been implicated in the development and progression of various human diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The ZNF286A gene has been extensively studied, and several studies have identified its involvement in various cellular processes. One of the most significant findings is that ZNF286A is highly expressed in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that ZNF286A may be a potential drug target for these diseases.

In addition to its involvement in neurodegenerative diseases, ZNF286A has also been linked to the development and progression of cancer. Several studies have shown that ZNF286A is highly expressed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. This suggests that targeting ZNF286A may be an effective way to treat cancer.

Another potential application of ZNF286A is as a biomarker for the diagnosis and prognosis of various diseases. Several studies have shown that ZNF286A is aberrantly expressed in various diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases. This suggests that measuring the expression of ZNF286A may be a useful diagnostic tool for these diseases.

The ZNF286A gene and its associated proteins have been implicated in the development and progression of various human diseases, including cancer and neurodegenerative diseases. Targeting ZNF286A may be an effective way to treat these diseases and improve patient outcomes.

Targeting ZNF286A

ZNF286A is a protein that is expressed in various tissues and cells of the human body. It is highly expressed in the brains of individuals with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that targeting ZNF286A may be an effective way to treat these diseases.

One potential way to target ZNF286A is through the use of small molecules that can modulate its expression. These small molecules can be designed to specifically interact with ZNF286A and modulate its activity. One of the most promising strategies for targeting ZNF286A is the use of small molecules that can inhibit its activity as a negative regulator of gene expression.

Another potential way to target ZNF286A is through the use of antibodies that recognize and target specific regions of the ZNF286A protein. These antibodies can be used to block ZNF286A's activity and prevent it from interacting with its target proteins. One of the most promising applications of antibodies is the use of monoclonal antibodies (MAbs) that recognize and target specific regions of ZNF286A.

In addition to small molecules and antibodies, another potential approach to targeting ZNF286A is through the use of RNA-based therapies. These therapies use small interfering RNA (siRNA) to silence ZNF286A, effectively removing its impact on gene expression. One of the most promising applications of RNA-based therapies is the use of siRNA

Protein Name: Zinc Finger Protein 286A

Functions: May be involved in transcriptional regulation

The "ZNF286A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF286A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1